Alpha-synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees

ABSTRACT Background Multiplications of the SNCA gene that encodes alpha‐synuclein are a rare cause of autosomal dominant Parkinson's disease (PD). Methods Here, we describe 2 novel families in which there is autosomal dominant PD associated with SNCA duplication, and we compare the clinical fea...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 28; no. 6; pp. 813 - 817
Main Authors: Elia, Antonio E., Petrucci, Simona, Fasano, Alfonso, Guidi, Marco, Valbonesi, Stefano, Bernardini, Laura, Consoli, Federica, Ferraris, Alessandro, Albanese, Alberto, Valente, Enza Maria
Format: Journal Article
Language:English
Published: United States Blackwell Publishing Ltd 01-06-2013
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Multiplications of the SNCA gene that encodes alpha‐synuclein are a rare cause of autosomal dominant Parkinson's disease (PD). Methods Here, we describe 2 novel families in which there is autosomal dominant PD associated with SNCA duplication, and we compare the clinical features of all known patients carrying 3 or 4 SNCA copies. Results Affected members in family A presented with early onset PD that was variably associated with nonmotor features, such as dysautonomia, cognitive deficits, and psychiatric disturbances. In family B, the clinical presentation ranged from early onset PD‐dementia with psychiatric disturbances to late onset PD with mild cognitive impairment. Conclusions The presence of 4 SNCA copies is associated with a rich phenotype, characterized by earlier onset of motor and nonmotor features compared with patients who bear 3 SNCA copies. The clinical spectrum associated with SNCA duplications is wide, even within a single family, suggesting a role for as yet unidentified genetic or environmental modifiers. © 2013 Movement Disorder Society
Bibliography:istex:1F3379552CE68FAE894F37B7BFCD53303E26F9EF
ark:/67375/WNG-NV0P4XRM-1
ArticleID:MDS25518
Full financial disclosures and author roles may be found in the online version of this article.
Nothing to report.
The research leading to these results has received funding from the Italian Ministry of Health (Ricerca Corrente 2012, Ricerca Finalizzata Malattie Rare 2008) and from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 241791 (European Project on Mendelian Forms of Parkinson's Disease [MEFOPA]).
Relevant conflicts of interest/financial disclosures
These authors contributed equally this work.
Funding agencies
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.25518